A Prospective, Single-Blind, Randomized, Multi-Center Study Comparing the Cypher Elite to the Cypher Bx Velocity Sirolimus-Eluting Stent Systems (ELITE)

Trial Profile

A Prospective, Single-Blind, Randomized, Multi-Center Study Comparing the Cypher Elite to the Cypher Bx Velocity Sirolimus-Eluting Stent Systems (ELITE)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Dec 2013

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Acute coronary syndromes; Angina pectoris; Coronary artery disease; Coronary artery restenosis; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms ELITE
  • Sponsors Cordis Corporation
  • Most Recent Events

    • 17 Dec 2013 Planned End Date changed from 1 Jun 2015 to 1 Sep 2014, according to ClinicalTrials.gov record.
    • 17 Mar 2009 Status changed from recruiting to active, no longer recruiting, according to a Cordis Corporation media release. Cordis plans to cease development of the Cypher Elite stent. Approximately 700 patients have been enrolled and will be followed for 5 years.
    • 07 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top